Additionally, as recently shown (Ketley et al., 2014; Wojciechowska et al., 2014), utilization of kinase inhibitors alleviated some of the molecular symptoms of DM1, among others, diminishing the nuclear fraction of mutant DMPK transcripts (Ketley A et al., IDMC-11, San Fransico 2017). The gene discussed is DMPK; the disease is myotonic dystrophy type 1.